PCT

PureCycle Technologies, Inc. (PCT) - 10-K Summary

Business Context and Reporting Period

Company: PureCycle Technologies, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: PCT is an early commercial-stage company focused on commercializing a patented dissolution recycling technology to convert waste polypropylene into near-virgin quality resin (PureFive®). The company operates a commercial-scale facility in Ironton, Ohio, and a Feed PreP facility in Denver, Pennsylvania. It holds a global license from The Procter & Gamble Company (P&G), which was amended in 2025 to permanently waive exclusivity clawback provisions for North American plants.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company reported minimal revenues and negative operating cash flow, relying on capital raises to fund operations.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $8.4 million in revenue in 2025, compared to zero in 2024, driven by initial sales of recycled resin.
• Net Loss Improvement: Net loss decreased by $106.6 million year-over-year. This improvement was significantly driven by a $61.7 million gain from the change in fair value of liability-classified warrants (compared to a $71.6 million loss in 2024) and a $21.2 million loss on extinguishment of debt in 2024 that did not recur in 2025.
• Capital Raises: In 2025, PCT raised approximately $369.9 million in gross proceeds through:
  • Issuance of Series B Convertible Perpetual Preferred Stock ($300.0 million).
  • Private placement of Common Stock ($33.0 million).
  • Sale of Revenue Bonds ($36.9 million net proceeds).
• Asset Write-down: A non-cash write-down of $15.1 million was recorded for long-lead equipment previously purchased for the Augusta Facility, which is being re-evaluated for use in other planned facilities.
• Liquidity: Cash and cash equivalents increased from $15.7 million to $156.7 million, alleviating the "substantial doubt" regarding the company's ability to continue as a going concern for the next 12 months.

Guidance, Outlook, and Risks

Outlook and Expansion:

• Thailand Facility: Planned 130 million lb/year facility; permitting begun; expected operational late 2027.
• Belgium Facility: Planned 130 million lb/year facility; permit application expected in 2026; operational mid-to-late 2028. Received notice of acceptance for a €40 million EU Innovation Fund grant.
• Augusta Facility: Plan modified to a single 300 million lb/year facility; construction start no later than March 2028; operational by 2030.

Management Commentary:

• The Ironton Facility achieved mechanical completion in 2023 but faces intermittent mechanical challenges preventing full capacity operations.
• Management concluded that the substantial doubt about the company's ability to continue as a going concern is no longer present due to the Series B Preferred Stock funding.

Key Risks and Contingencies:

• Operational Scalability: No guarantee the technology is scalable to commercial profitability; Ironton Facility has not yet achieved full design capacity.
• Regulatory Approvals: Continued reliance on FDA Letters of No Objection (LNO) for food-grade applications and pending EU/EFSA approvals for international expansion.
• Debt and Liquidity: Total indebtedness of $363.7 million with restrictive covenants. Future expansion depends on additional financing.
• Legal Proceedings: An arbitration award of approximately $15.0 million was received against PCT regarding the Ironton Facility construction (Denham-Blythe). PCT has accrued $23.1 million total for this matter and is evaluating an appeal.
• License Agreement: P&G retains rights to clawback exclusivity for non-North American regions if specific construction and sales deadlines are not met.

Investor Verification Checklist

• Ironton Facility Certification: Verify the status of the independent engineer's (Leidos) certification of operational performance, which is a condition for earn-out shares and full commercial operation.
• Series B Preferred Stock Terms: Review the specific redemption triggers and conversion mechanics of the $300 million Series B Convertible Perpetual Preferred Stock issued in June 2025.
• Arbitration Appeal: Monitor the outcome of the appeal regarding the $15.0 million Denham-Blythe arbitration award and its impact on cash reserves.
• Feedstock Supply: Assess the reliability and cost of polypropylene feedstock supply chains, particularly for the new Feed PreP facilities.
• Regulatory Milestones: Track the timeline for EU/EFSA authorization for the Belgium Facility and FDA LNO expansions for new feedstock sources.